Research libraryPeptide science basics
Five Research Peptides Compared: Structure and Mechanism
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
A handful of research peptides come up over and over, and they get lumped together not because they do the same job but because they orbit a few shared pathways. This overview takes the five researchers reach for most: CJC-1295, Ipamorelin, BPC-157, MK-677, and IGF-1 LR3. For each, we stick to what the molecule is, which receptor or pathway it touches, and what the primary papers actually measured. Every claim is linked, so check our work.
Key findings
- CJC-1295, a GHRH analog, grabs onto albumin and rides it for roughly 8 days [1].
- Ipamorelin showed up in 1998 as the first selective GH secretagogue at GHS-R1a [2].
- BPC-157, a stable 15 residue gastric peptide, turns up in rat tendon and tendocyte work [3].
- MK-677 (ibutamoren) hits that same GHS-R1a receptor, but it’s a small molecule you can take by mouth [4].
- IGF-1 LR3, an engineered IGF-I variant, holds its binding proteins loosely [5][6].
How these compounds relate
Three of the five sit on the growth hormone axis, but they hit it at different spots. CJC-1295 is a GHRH analog, so it works at the GHRH receptor. Ipamorelin and MK-677 are secretagogues acting at GHS-R1a, the same receptor your own ghrelin uses [2][4]. IGF-1 LR3 is further downstream, an analog of the growth factor itself. And BPC-157 is the odd one out, a gastric peptide from a separate line of tissue research [3]. Grouping them only makes sense if you keep those mechanistic differences straight, which is where a lot of older content fell apart.
CJC-1295
First up, CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH). Its signature move: a chemical modification that lets it bind covalently to endogenous albumin, stretching its half-life to roughly 8 days in the work by Alba and colleagues [1]. In GHRH knockout mice, once-daily CJC-1295 brought body length back to normal [1]. In healthy men, CJC-1295 held the natural pulsatile pattern of GH secretion while lifting trough levels about 7.5-fold [7]. Long duration plus preserved pulsatility, that pairing is why it’s studied as a GHRH analog rather than a blunt stimulator. For the DAC versus no-DAC split, see our CJC-1295 comparison.
Ipamorelin
Next, Ipamorelin, a five-residue secretagogue. Raun and colleagues rolled it out in 1998 and called it the first selective GH secretagogue, because it set off GH release at GHS-R1a while mostly skipping the off-target pituitary noise the older peptides dragged along [2]. People keep reaching for it as a comparison point for one reason: that selectivity. Our Ipamorelin overview goes deeper on the receptor behavior.
BPC-157
Then there’s BPC-157, the outlier. It’s a pentadecapeptide, 15 residues, pulled from a protein in gastric juice, and the literature on it is mostly preclinical. Staresinic and colleagues, for instance, found BPC-157 changed measured outcomes in a transected rat Achilles tendon model and pushed tendocyte growth in a dish [3]. We’ll leave it there, flatly, because that’s all the paper is: one rodent-and-cell study with specific endpoints. Analytically, people often note it holds up better than many peptides.
MK-677 (ibutamoren)
Here’s the odd member: MK-677, or ibutamoren. Not a peptide. It’s a small molecule, taken by mouth, that acts as a GH secretagogue at GHS-R1a, the very receptor Ipamorelin uses. Lee and colleagues fed the orally active MK-677 to rats and tracked what happened to their growth parameters [4]. The mouth part is the whole story, really, since it separates MK-677 from the peptide secretagogues, which don’t survive the gut. It rides along in these roundups anyway, because everyone keeps cross-referencing it despite the chemistry being different.
IGF-1 LR3
IGF-1 LR3 is an engineered variant of insulin-like growth factor 1, carrying a 13 residue N-terminal extension and an arginine swap at position 3. Those edits trace to the Long [Arg3]-IGF-I construct Francis and colleagues first made in 1992 [5], and the substitution weakens the molecule’s grip on IGF binding proteins [5]. Tomas and colleagues then showed that IGF-I variants binding those proteins poorly acted more potently, and for longer, than native IGF-I in pigs and marmosets [6]. For the full breakdown, see our IGF-1 LR3 overview.
| Compound | Type | Target / pathway | Notable measured property |
|---|---|---|---|
| CJC-1295 | GHRH analog (peptide) | GHRH receptor | ~8 day half-life via albumin binding [1] |
| Ipamorelin | Pentapeptide secretagogue | GHS-R1a | First selective GHS [2] |
| BPC-157 | Pentadecapeptide | Tissue/tendon models | Stimulated tendocyte growth in vitro [3] |
| MK-677 | Small molecule | GHS-R1a | Orally active [4] |
| IGF-1 LR3 | IGF-I analog | IGF-1 receptor | Reduced IGFBP affinity [5][6] |
A note on quality verification
Across all five, the two questions never change. Is it actually the molecule on the label? And how pure is it? HPLC handles the purity question; mass spectrometry handles identity, checked against the expected mass. Clear that bar first, always. For how that verification works, see our overview of third-party tested peptides.
Frequently asked questions
Do CJC-1295 and Ipamorelin share a receptor?
They don’t. CJC-1295 works at the GHRH receptor as a GHRH analog, while Ipamorelin is a secretagogue at GHS-R1a [1][2].
Is MK-677 a peptide?
Nope, it’s a small molecule you can take orally, even though it lands on the same GHS-R1a receptor as the peptide secretagogues [4].
How is IGF-1 LR3 different from native IGF-I?
It carries an N-terminal extension and an Arg3 swap, and together those loosen its hold on IGF binding proteins [5][6].
References
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PMID 16822960
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID 14554208
- Lee J, Kwon A, Chae HW, et al. Effect of the orally active growth hormone secretagogue MK-677 on somatic growth in rats. Yonsei Med J. 2018. PMID 30450851
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992. PMID 1378742
- Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997. PMID 9415072
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654